Gotham Asset Management’s Summit Therapeutics SMMT Stock Holding History

Gotham Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Hold	15,727	–	–	﹤0.01%	1709
2026 Q1	$298K	Hold	15,727	–	–	﹤0.01%	1607
2025 Q4	$275K	Hold	15,727	–	–	﹤0.01%	1587
2025 Q3	$325K	Sell	15,727 -2	-0%	-$49	﹤0.01%	1495
2025 Q2	$335K	Sell	15,729 -56	-0.4%	-$1.28K	﹤0.01%	1429
2025 Q1	$304K	Hold	15,785	–	–	﹤0.01%	1356
2024 Q4	$282K	Sell	15,785 -123	-0.8%	-$2.38K	﹤0.01%	1289
2024 Q3	$348K	Sell	15,908 -3,592	-18%	-$50.2K	﹤0.01%	1191
2024 Q2	$152K	Buy	+19,500	New	+$105K	﹤0.01%	1360

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Gotham Asset Management's SMMT Position: Q2 2026 in Review

Gotham Asset Management held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 15,727 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

Gotham Asset Management first reported a position in SMMT in Q2 2024 and has held it in 9 quarters since. The position peaked at $348K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Gotham Asset Management held 15,727 shares of Summit Therapeutics worth $229K as of Q2 2026.
Gotham Asset Management left its Summit Therapeutics share count unchanged in Q2 2026.
Summit Therapeutics made up ﹤0.01% of Gotham Asset Management's portfolio in Q2 2026, its #1709 holding.
Gotham Asset Management first reported a position in Summit Therapeutics in Q2 2024 and has held it in 9 quarters since.
Gotham Asset Management's Summit Therapeutics position peaked at $348K in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.